Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


With $20.7 Million Series A Cash, RaNA Seeks To Be A Groundbreaker In Long Non-Coding RNA Therapeutics

This article was originally published in The Pink Sheet Daily

Executive Summary

Biotech hopes to begin IND-enabling studies in 2013 and bring first candidate into the clinic in 2014 in a new field it believes will have applicability in numerous therapeutic areas.

You may also be interested in...

Ag-Bio Alliance With Monsanto Brings Alnylam Cash For “5x15” Programs

Alnylam will license its IP estate to agriculture giant Monsanto over 10 years, in turn getting a $29.2 million upfront payment that it will put toward further development of RNAi therapeutics.

Start-Up Quarterly Statistics, Q1 2012

Biopharma start-ups raised $338.1 million – 51% less than in Q4 2011. Device companies brought in $123.7 million and diagnostics firms raised $99.3 million; Series C rounds generated more money in both the device and diagnostic sectors than any other financing type. Cancer was the most prevalent therapeutic area for biopharma alliances. During Q1, M&As across biopharma and diagnostic industries were valued at a total of $471 million.

Financings Of The Fortnight Applies Its Own Lens To Early-Stage Investments

Plus news on recent financings by Neurocrine Biosciences, Prosensa, RaNA Therapeutics and Trius Therapeutics.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts